Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Pia S Pannaraj · CHILDREN'S HOSPITAL OF LOS ANGELES · 2023 · $1 — PROJECT SUMMARY COVID-19 cases and hospitalizations in children have increased dramatically worldwide. Although most COVID- 19 is mild in children, severe illness and post-infectious complications can occur. We and others have found that children are an important source of household and community tr…
MICHAEL N STARNBACH · HARVARD MEDICAL SCHOOL · 2023 · $247,824 — Chlamydia trachomatis is an obligate intracellular bacterium and the most prevalent sexually transmitted infection in the United States. If untreated, infection can lead to pelvic inflammatory disease, ectopic pregnancy, and infertility. Although C. trachomatis infection is treatable with antibiotic…
Nehemiah Seth Alvarez · EASTERN VIRGINIA MEDICAL SCHOOL · 2023 · $108,996 — ABSTRACT Infertility is a major reproductive health issue that affects ~12% of reproductively aged women in the United States. Approximately 1-3% of infertile or subfertile women have oocytes that arrest in meiosis or shortly after fertilization due to genetic variants. Unfortunately, there are no t…
Andrea L Kasinski · PURDUE UNIVERSITY · 2023 · $386,276 — PROJECT SUMMARY Like the challenges and skepticism that faced the antibody therapeutics field over a decade ago, RNA therapeutics is facing the same. And, like the antibody therapeutics field, we are beginning to realize the clinical impact of RNA therapeutics amiss these challenges. This is most cl…
VICTOR Robert DEFILIPPIS · OREGON HEALTH & SCIENCE UNIVERSITY · 2023 · $773,026 — PROJECT SUMMARY The goals of this R01 proposal include the molecular and immunological characterization of vaccine adjuvant activity associated with processes mediated by the protein Stimulator of Interferon Genes (STING). Two vital insufficiencies are currently evident regarding adjuvanted human va…
Kay Lynn Medina · MAYO CLINIC ROCHESTER · 2023 · $318,000 — PROJECT SUMMARY Steady-state hematopoiesis in bone marrow is critical for maintenance of blood cell genesis and immune competence throughout life. Concomitant with aging, the bone marrow hematopoietic stem cell (HSC) compartment undergoes cell intrinsic and extrinsic changes that biases hematopoieti…
Guizhi Zhu · VIRGINIA COMMONWEALTH UNIVERSITY · 2023 · $552,247 — Small circular mRNA vaccines Abstract: Vaccines save numerous lives each year. Conventional vaccines based on pathogens, DNA, proteins, or peptides are associated with poor pharmacokinetics, limited biostability, preexisting anti-viral-vector immunity, weak immunogenicity, or safety concerns over ge…
Daniel Pearce Depledge · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2023 · $545,420 — 7. PROJECT SUMMARY / ABSTRACT Chemical modification of mRNA provides a powerful means to dynamically alter gene expression in eukaryotes via epitranscriptomic changes. In particular, methylation of adenosine at the N6 position (m6A) constitutes the most widespread internal base modification to mRNA.…
CHRISTOPHER A BENEDICT · LA JOLLA INSTITUTE FOR IMMUNOLOGY · 2023 · $565,653 — Summary Cytomegalovirus (CMV, a b-herpesvirus) establishes a persistent infection that is endemic in humans and mice. CMV causes acute clinical disease only if immunity is naïve or compromised, exemplifying how coevolution with its host over millennia has resulted in a largely non-pathogenic détente…
Krzysztof Palczewski · UNIVERSITY OF CALIFORNIA-IRVINE · 2023 · $602,331 — SUMMARY Inherited retinal disorders are a genetically heterogeneous group of blinding diseases that have significant impact on quality of life. Therapeutic approaches have lagged significantly behind initial identification of the genetic bases for these diseases. However, there are some striking suc…
Michela Locci · UNIVERSITY OF PENNSYLVANIA · 2023 · $668,622 — SUMMARY Messenger RNA (mRNA) vaccines represent a powerful vaccine approach for the induction of protective immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since this vaccine platform was approved for human use in 2020 for the first time, little is known about …
Sharon Aviran · UNIVERSITY OF CALIFORNIA AT DAVIS · 2023 · $204,073 — Natural and synthetic RNAs play key roles in cellular function, biotechnology, and medicine. RNAs fold into intricate structures, which often drive their functions, thus determining RNA structure is fundamental to biology and biotechnology. Computational thermodynamics-based secondary structure mode…
MING LUO · GEORGIA STATE UNIVERSITY · 2023 · $540,203 — The devastating impact on public health, global economy and social stability incurred by the COVID-19 pandemic in the last two years has highlighted the importance of basic research into zoonotic pathogens. This application describes structural and functional studies into the rodent-borne human path…
Dan H. Barouch · FRED HUTCHINSON CANCER CENTER · 2023 · $19,404,520 — Project Abstract This proposal outlines the scientific agenda for the COVID-19 Prevention Network (CoVPN) Vaccines Leadership Operations Center (LOC) for implementation of the COVID-19 vaccine efficacy trial, CoVPN 3008 (the Ubuntu study) entitled “Multi-Center, Randomized, Efficacy Study of COVID-1…
TERRY L. SHEPPARD · KEYSTONE SYMPOSIA · 2023 · $5,500 — ABSTRACT Support is requested for a Keystone Symposia conference entitled T and B Cell Collaboration in Germinal Centers and Beyond, organized by Drs. Shane Crotty, Michela Locci and Jennifer Gommerman. The conference will be held in Whistler, British Columbia, Canada from October 1-4, 2023. T cell/…
Leonidas Stamatatos · FRED HUTCHINSON CANCER CENTER · 2023 · $589,260 — PROJECT SUMMARY An effective HIV-1 vaccine will be one that elicits diverse anti-viral immune responses, including broadly neutralizing antibodies (bnAbs). We are focused on the elicitation of anti-CD4-binding site (CD4-BS) bnAbs, including VRC01-class bnAbs, through a guided immunization approach w…
James M Dubois · WASHINGTON UNIVERSITY · 2023 · $473,882 — Project Summary Religion is a primary driver of concerns with genomics and genomic healthcare (GGH). It is vital for research on the ethical, legal, and social implications (ELSI) of genomics to understand the role of religion in shaping public attitudes toward GGH. Ninety percent of the US public …
Shane P Crotty · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2023 · $779,142 — Project Summary Preclinical studies and early stage human trials evaluating passively transferred broadly neutralizing antibodies (bnAbs) suggest that a vaccine capable of eliciting bnAbs would provide effective protection from HIV infection. However, the difficulty of inducing bnAbs through vaccina…
Donna L. Farber · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2023 · $807,646 — PROJECT SUMMARY Immune system development during infancy and childhood sets the stage for a lifetime of protective immunity. Infants and children are known to be more susceptible to ubiquitous respiratory and mucosal pathogens for which adults have prior exposures. However, our recent experience in …
Ellen Elizabeth Sparger · TENDEL THERAPIES INC. · 2023 · $1,000,000 — Tendel’s CoTend-s3B SARS-CoV-2 booster vaccine targets T follicular helper (Tfh) cells to generate extraordinarily broad and long-lived antibody responses, which are required for resilient vaccines that maintain protection over long periods. The vaccine candidate incorporates the “s3” targeting moie…